Présentation

P3-3 The CEPI R&D Funding Model

Aurélia Nguyen

Auteurs

Langues

  • Anglais

Année de publication

2025

Type

Présentation

Catégories

  • Initiatives mondiales

GVIRF-2025

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
GVIRF 2025 Call for Abstracts2024Poster/infographicAnglais
GVIRF 2025 Detailed AgendaGVIRF Secretariat2025WebinarAnglais
P1-1 Innovations in vaccine discoveryGalit Alter2025PresentationAnglais
P1-2 Innovation in vaccine developmentAndrew Pollard2025PresentationAnglais
P1-3 Delivering vaccines: Vaccine innovation ecosystem past, present, and futureAnne Schuchat2025PresentationAnglais
P1-4 Vaccination overview in BrazilEder Gatti2025PresentationAnglais
P2-1 Pathogen prioritization at the global level: WHO Global Priority Endemic Pathogens for Vaccine R&DMateusz Hasso-Agopsowicz2025PresentationAnglais
P2-2 Prioritizing pathogens with epidemic and pandemic potentialJakob Cramer2025PresentationAnglais
P2-3 Setting R&D Priorities – Bio-Manguinhos’ PerspectivesRicardo de Godoi2025PresentationAnglais
P2-4 Development of vaccines for global use: Role of the vaccine industryLuis Jodar2025PresentationAnglais
P3-1 The Value of Health R&D –The Return on InvestmentNick Chapman2025PresentationAnglais
P3-2 The infectious diseases vaccines R&D financing landscape​: An Industrial perspective​Nick Jackson2025PresentationAnglais
P3-3 The CEPI R&D Funding ModelAurélia Nguyen2025PresentationAnglais
P4-1 Introduction: Why is innovation in clinical trials needed now?Peter Dull2025PresentationAnglais
P4-2 Clinical immunobridging strategy to support licensure of preventive vaccinesMarion Gruber2025PresentationAnglais
P4-3 A systematic approach to identification of correlates of protectionDeborah King2025PresentationAnglais
P4-4 Vaccine efficacy evidence generation in outbreaksJakob Cramer2025PresentationAnglais
P5-1 Overview of arbovirus vaccinesMelanie Saville2025PresentationAnglais
P5-2 What is the current state of dengue vaccine development and new technologies?Esper Kallas2025PresentationAnglais
P5-3 Approved Chikungunya vaccinesMarco Cavaleri2025PresentationAnglais
P5-4 Yellow Fever Vaccination: Fractional dosing and one versus two life-time dosesPatricia Mouta Nunes de Oliveira2025PresentationAnglais
P6-1 What have we learned in the COVID19 pandemic?Ricardo Tostes Gazzinelli2025PresentationAnglais
P6-2 Global and Regional Vaccine R&D UpdateMaria Elena Bottazzi2025PresentationAnglais
P6-3 mRNA vaccine production capacity building in Latin AmericaTomás Pippo2025PresentationAnglais
P6-4 Case studies for clinical trial capacity in the regionSue Ann Costa Clemens 2025PresentationAnglais
P7-1 Predicting infectious disease responses to climate changeSonia Altizer2025PresentationAnglais
P7-2 Oceans, climate and health: The cholera paradigmRita Colwell2025PresentationAnglais
P7-3 Climate change and vaccine-preventable diseasesNeil Ferguson2025PresentationAnglais
P8-1 Equitable and sustainable access to new vaccines: Where are we and what will it take?Tara Prasad2025PresentationAnglais
P8-2 Regional Revolving FundsSantiago Cornejo2025PresentationAnglais
W1-1 Trends in vaccine technology innovationsJorge Kalil2025PresentationAnglais
W1-2 Novel adjuvants and mucosal vaccination strategiesEd Lavelle2025PresentationAnglais
W1-3 Oral delivery of biologicsGiovanni Traverso2025PresentationAnglais
W1-4 Glycoconjugate Vaccines: Molecular architecture and controlled heterogeneityJohn Hennessey2025PresentationAnglais
W1-5 Novel Vaccines Technologies: Moving to the ClinicHana El Sahly2025PresentationAnglais
W2-1 AMR burden and prevalence: Global perspective and a vision from Latin AmericaCarlos Kiffer2025PresentationAnglais
W2-2 Scientific evidence demonstrating the impact of vaccines on Antimicrobial ResistanceMateusz Hasso-Agopsowicz2025PresentationAnglais
W2-3 Vaccine development against AMR priority pathogens: Staphylococcus aureus, Klebsiella pneumoniae and extraintestinal pathogenic Escherichia coliRino Rappuoli2025PresentationAnglais
W3-1 What is implementation research and why should it be mainstreamed into immunization systems in the African Region?Abdu Adamu2025PresentationAnglais
W3-2 Economic evidence generation through field-based implementation researchJung-Seok Lee2025PresentationAnglais
W3-3 How has implementation evidence informed Indonesia’s vaccine introduction policies? Lessons learned from the CAPACITI decision-support toolAuliya Suwantika2025PresentationAnglais
W3-4 The current experience of conducting implementation research to inform malaria vaccine roll-outKwaku Poku Asante2025PresentationAnglais
W4-1 Accelerating the development of new tuberculosis (TB) vaccines for adults and adolescentsWillem Hanekom2025PresentationAnglais
W4-2 Challenges and Opportunities in TB Vaccine DevelopmentAnn Ginsberg2025PresentationAnglais
W4-3 Feasibility and potential consequences of including asymptomatic TB in the primary endpoint in vaccine licensure trialsRichard White2025PresentationAnglais
W4-4 The considerations of including people deprived of liberty (PDL) in TB vaccine licensure trialsJulio Croda2025PresentationAnglais
W5-1 Passive immunization in preventing disease: Overview, rationale, and common challengesErin Sparrow2025PresentationAnglais
W5-2 Evaluating impact of interventions for group B streptococcus and respiratory syncytial virus in infantsAnne Schuchat2025PresentationAnglais
W5-3 Approaches to support maternal vaccine licensure and adoptionAnnaliesa Anderson2025PresentationAnglais
W5-4 Implementation and vaccine effectiveness studies of the RSV vaccine in ArgentinaSantiago Olszevicki2025PresentationAnglais

Ajouté par: Angela Hwang

Ajouté le: 2025-03-28 20:05:22

Consultations: 1488

Liens

Fichier téléchargé

P3-4 Nguyen.pdf

Cliquez pour télécharger

Ajouter une ressource